These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 18463327)
1. Novel cytotoxic agents: epothilones. Goodin S Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327 [TBL] [Abstract][Full Text] [Related]
2. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [TBL] [Abstract][Full Text] [Related]
3. Application of epothilones in breast cancer therapy. Cianfrocca M Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044 [TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679 [TBL] [Abstract][Full Text] [Related]
5. Clinical studies with epothilones for the treatment of metastatic breast cancer. Vahdat LT Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796 [TBL] [Abstract][Full Text] [Related]
6. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Pronzato P Drugs; 2008; 68(2):139-46. PubMed ID: 18197722 [TBL] [Abstract][Full Text] [Related]
7. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Rivera E; Lee J; Davies A Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with epothilones in patients with breast cancer. Buzdar AU Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402 [TBL] [Abstract][Full Text] [Related]
9. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Yardley DA Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502 [TBL] [Abstract][Full Text] [Related]
10. Ixabepilone, a new treatment option for metastatic breast cancer. Toppmeyer DL; Goodin S Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567 [TBL] [Abstract][Full Text] [Related]
11. Development of other microtubule-stabilizer families: the epothilones and their derivatives. Brogdon CF; Lee FY; Canetta RM Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663 [TBL] [Abstract][Full Text] [Related]
12. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Steinberg M Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366 [TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Vahdat L Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531 [TBL] [Abstract][Full Text] [Related]
14. Advances in breast cancer treatment: the emerging role of ixabepilone. Frye DK Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882 [TBL] [Abstract][Full Text] [Related]
15. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. Boehnke Michaud L J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553 [TBL] [Abstract][Full Text] [Related]
16. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. Goodin S Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860 [TBL] [Abstract][Full Text] [Related]
17. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060 [TBL] [Abstract][Full Text] [Related]
18. Ixabepilone for the treatment of taxane-refractory breast cancer. Moulder SL Future Oncol; 2008 Jun; 4(3):333-40. PubMed ID: 18518758 [TBL] [Abstract][Full Text] [Related]
19. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Fornier MN Clin Breast Cancer; 2007 Oct; 7(10):757-63. PubMed ID: 18021476 [TBL] [Abstract][Full Text] [Related]
20. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Lee JJ; Kelly WK Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]